Robert A. Langish

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

New horizons in hypoxia signaling pathways

Mechanisms of hypoxia signalling: new implications for nephrology

Targeting HIF2 in Clear Cell Renal Cell Carcinoma

Allosteric inhibition of hypoxia inducible factor-2 with small molecules

Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors

Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes

The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules

The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor